In utero exposure to the endocrine disrupting compound bisphenol A (BPA) is known to disrupt mammary gland development and increase tumor susceptibility in rodents. It is unclear whether different periods of in utero development might be more susceptible to BPA exposure. We exposed pregnant CD-1 mice to BPA at different times during gestation that correspond to specific milestones of in utero mammary gland development. The mammary glands of early-life and adult female mice, exposed in utero to BPA, were morphologically and molecularly (estrogen receptor-a and Ki67) evaluated for developmental abnormalities. We found that BPA treatment occurring before mammary bud invasion into the mesenchyme [embryonic day (E)12.5] incompletely resulted in the measured phenotypes of mammary gland defects. Exposing mice up to the point at which the epithelium extends into the precursor fat pad (E16.5) resulted in a nearly complete BPA phenotype and exposure during epithelial extension (E15.5 to E18.5) resulted in a partial phenotype. Furthermore, the relative differences in phenotypes between exposure windows highlight the substantial correlations between early-life molecular changes (estrogen receptor-a and Ki67) in the stroma and the epithelial elongation defects in mammary development. These data further implicate BPA action in the stroma as a critical mediator of epithelial phenotypes. (Endocrinology 158: 3435-3447, 2017) E strogen signaling is critical for breast organogenesis and development. Exogenous estrogenic exposure during in utero development can have lifelong consequences. The first evidence of risk associated with in utero estrogen exposure was with the use of synthetic estrogen, diethylstilbestrol (DES), prescribed to women beginning in the 1940s. The use of DES was discontinued when the daughters exposed in utero-"DES daughters"-had a 40 times increased risk of clear cell adenocarcinoma of the vagina and cervix (1-3). Later investigation of these women revealed a twofold increased risk of breast cancer after age 40 years (2). Although synthetic estrogens are no longer prescribed to pregnant women, rodent studies have demonstrated that in utero exposure to environmental estrogens, such as bisphenol A (BPA), can also contribute to mammary gland tumor formation (4-6). BPA, similar to DES, has been shown to aberrantly bind and activate the estrogen receptor (ER) (7, 8) .
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In utero exposure to the endocrine disrupting compound bisphenol A (BPA) is known to disrupt mammary gland development and increase tumor susceptibility in rodents. It is unclear whether different periods of in utero development might be more susceptible to BPA exposure. We exposed pregnant CD-1 mice to BPA at different times during gestation that correspond to specific milestones of in utero mammary gland development. The mammary glands of early-life and adult female mice, exposed in utero to BPA, were morphologically and molecularly (estrogen receptor-a and Ki67) evaluated for developmental abnormalities. We found that BPA treatment occurring before mammary bud invasion into the mesenchyme [embryonic day (E)12.5] incompletely resulted in the measured phenotypes of mammary gland defects. Exposing mice up to the point at which the epithelium extends into the precursor fat pad (E16.5) resulted in a nearly complete BPA phenotype and exposure during epithelial extension (E15.5 to E18.5) resulted in a partial phenotype. Furthermore, the relative differences in phenotypes between exposure windows highlight the substantial correlations between early-life molecular changes (estrogen receptor-a and Ki67) in the stroma and the epithelial elongation defects in mammary development. These data further implicate BPA action in the stroma as a critical mediator of epithelial phenotypes. (Endocrinology 158: 3435-3447, 2017) E strogen signaling is critical for breast organogenesis and development. Exogenous estrogenic exposure during in utero development can have lifelong consequences. The first evidence of risk associated with in utero estrogen exposure was with the use of synthetic estrogen, diethylstilbestrol (DES), prescribed to women beginning in the 1940s. The use of DES was discontinued when the daughters exposed in utero-"DES daughters"-had a 40 times increased risk of clear cell adenocarcinoma of the vagina and cervix (1) (2) (3) . Later investigation of these women revealed a twofold increased risk of breast cancer after age 40 years (2) . Although synthetic estrogens are no longer prescribed to pregnant women, rodent studies have demonstrated that in utero exposure to environmental estrogens, such as bisphenol A (BPA), can also contribute to mammary gland tumor formation (4) (5) (6) . BPA, similar to DES, has been shown to aberrantly bind and activate the estrogen receptor (ER) (7, 8) .
BPA is an industrial plasticizer that is ubiquitous in the environment, having been detected in .95% of the U.S. population, including human amniotic fluids (9) (10) (11) (12) (13) (14) (15) (16) . Although the effects of in utero BPA exposure in humans have yet to be well-defined, the detriment of this exposure has been well-characterized in murine models (4, 6, (17) (18) (19) (20) (21) (22) (23) (24) , demonstrating increased cancer susceptibility similar to that seen in DES-treated rodents (25) (26) (27) . Specifically, in utero BPA-treated early-life mammary glands have previously been shown to have more terminal end buds (TEBs) when normalized to the reduced epithelial area (19) , a reduced number of terminal duct ends (TDEs), decreased epithelial elongation through the fat pad, and less stromal proliferation (4, 18, 28) . Furthermore, in utero BPA exposure increases susceptibility to cancer through the development of ductal hyperplasia (29) and results in a greater incidence of tumors in models using predisposed transgenic alterations (NCR nu/nu, MMTV-erbB2) (30) or through a second assault by a carcinogen (e.g., 7,12-dimethylbenz[a]anthracene) (5) . Similar phenotypes have been reported in rats (6, 20, 31, 32) , in which perinatal BPA exposure induced malignancies and lesions-without additional exposure to a carcinogen (33)-and in the rhesus monkey through altered development (34) .
During embryogenesis, the fetal mammary gland progresses through several developmental stages that are independent of estrogen activity (35) (36) (37) (38) . ERa knockout mice have normal mammary glands at birth, demonstrating that the receptor is only required after birth for mammary development (39, 40) . However, it is unclear whether perinatal receptor activity is essential for driving BPA-induced pathologies. In utero mammary gland development begins between embryonic day (E)10.5 and E11.5 (41) , when the primordial mammary epithelial buds form along the milk line. At that point, the mammary mesenchyme condenses underneath the developing epithelial bud (42) and serves as the only ERa-expressing compartment of the developing gland (22, 43) . Mouse ERa expression has been reported in the epithelium only in postnatal development (44) . Once these developing epithelial buds sink beneath the epidermis starting at E13.5, they remain completely surrounded by this ERapositive mesenchyme until approximately E16.5 (42) , when a boost in proliferation causes the bud to sprout out of this mesenchyme toward the fat pad and into primary rudimental branching (41) . It is unclear whether the mammary gland has different susceptibilities to endocrine disrupting chemical exposure across these in utero developmental stages. However, reproductive tract tumors found in DES daughters were specifically associated with first trimester exposure (1-3). Analysis of DES exposure windows and breast cancer has not been performed; however, because the interaction of the perinatal ERa-positive mesenchyme and the ERa-negative epithelial bud is developmentally modulated, the effect of estrogenic compounds on the developing gland could have very discrete windows of susceptibility.
In the present study, we examined different windows of in utero exposure to BPA to narrow the scope of the developmental mechanisms responsible for the previously observed later-life epithelial defects and cancer susceptibility. Although previous studies have extensively demonstrated other developmental time points of sensitivity, including peripubertal and pregnancy (30, 31, (45) (46) (47) (48) , we focused our efforts on the susceptibility of in utero exposures. BPA has been shown to cross the placental barrier and has been detected in human amniotic fluid (9) (10) (11) (12) (13) (14) (15) . Thus, we treated pregnant CD-1 mice to a low dose (25 mg/kg body weight/day) of BPA during different periods of gestation. We then analyzed several previously reported phenotypes of these exposures in in utero-treated female offspring (4, 5, 17, 18, 20, 21, 34) to determine whether different time points of BPA exposure resulted in specific mammary gland defects. We found that treating mice after the ERa-negative mammary epithelial bud had completely sunk into the condensed ERa-positive mesenchyme (E12.5) was sufficient to cause previously reported phenotypes. Furthermore, we revealed a substantial correlation linking decreased stromal proliferation and increased ERa expression to delayed epithelial growth in early development, suggesting that these defects might be directed by mesenchymal dysfunction. Thus, our findings support a role for BPA to disrupt tissue compartment interactions of the developing mammary gland, driving the later-life epithelial defects and cancer susceptibility previously observed.
Materials and Methods

Animals
Animal experiments were performed in compliance with protocols approved by The Ohio State University institutional animal care and use committee (protocol no. 2013A00000030) and in accordance with the accepted standard of humane animal care. Only female CD-1 mice were used in the present study. The mice were maintained in polysulfone cages and fed a diet containing minimal levels of phytoestrogen (2019X Teklad Rodent Diets; Harlan Laboratories Inc., Indianapolis, IN). Sexually mature female CD-1 mice (aged $8 weeks) were mated, and identification of a vaginal plug was taken to be embryonic day (E) 0.5. Pregnant mice were injected intraperitoneally (IP) daily with sesame oil vehicle control or 25 mg/kg body weight BPA (in sesame oil) between E8.5 and E18.5. This dose has been previously described to lead to alterations in the mammary gland and uterus of exposed mice (18, 23) . Mice from the same litter were divided among the different endpoints (4.7, 14, and 20 weeks) to minimize littermates being used for the same analysis. In sample sets using littermates, the litters were compared against the remaining samples to determine whether the differences in the litter were statistically significant. In cases in which the differences were statistically significant, the average of the littermates was used as one data point.
In utero exposure to BPA and tissue preparation
To evaluate perinatal ERa expression in the developing mammary gland (Fig. 1) , treated pregnant mice were euthanized at E13.5, E15.5, E16.5, E17.5, E18.5, and E19.5. The developing fetuses were harvested and genotyped for sex to omit males, fixed for 72 hours in 10% neutral buffered formalin, transferred to 70% ethanol embedded in paraffin, and cut in 6-mM sections. The sections were collected by taking four consecutive 6-mM sections, skipping 30 mM of tissue, and repeating the four 6-mM sections to encounter one of the developing placodes. Spacing out consecutive cuts was used to provide favorability in locating mammary placodes and later epithelial rudiments. Thus, the images are representative ob- The in utero dosing schemes used to examine discrete windows of exposure, and administered by IP injection as described, corresponded to E8.5 to E12.5 (BPA1), the period during milk line formation but before bud invagination into the mesenchyme; E8.5 to E16.5 (BPA2), the period from milk line formation through bud invagination but before epithelial invasion into the fat pad; E15.5 to E18.5 (BPA3), the period in which epithelial extension begins toward the fat pad until it has begun branching; and E8.5 to E18.5 (BPA4), the duration of exposure that resulted in previously reported phenotypes [ Fig. 2(a) ].
For the purpose of morphological analysis of susceptibility, the fourth inguinal mammary gland on each side of the mouse at 4.5 (early-life, n $ 7), 14, and 20 weeks (adult/later-life, n $ 9 and 3, respectively) was harvested for each treatment group. For all mice aged $ 8 weeks, the estrus cycle was monitored by vaginal cytology (49) (50) (51) (52) , and glands were harvested during the estrous stage. The stage of estrus was confirmed by hematoxylin and eosin analysis of the dissected uterus, ovaries, and vagina from each mouse (50, 52) . For each mouse, one gland was whole mounted and carmine-aluminum stained, (using the National Toxicology Program Animal Studies Protocol, Section XIII, Appendix 6, Section E) (53) for morphological analyses. The other gland was fixed in 10% neutral-buffered formalin for 24 hours, transferred to 70% ethanol, embedded in paraffin, and cut in 4-mM sections for immunohistochemical analysis. Thus, the presented data were from matched mammary glands for whole mount morphological analyses and immunohistochemistry (IHC).
Amniotic fluid sample preparation and high-performance liquid chromatography with fluorescence detection Beginning at E8.5, pregnant CD-1 female mice were injected IP as described until E15.5. At E15.5, the mice were injected IP with a final dose of BPA or oil vehicle and harvested 1 hour later for fetal amniotic fluid. Fluid from all embryonic sacs from a single female mouse was pooled for each treatment replicate. The liquid from the amniotic fluid samples (average,~600 mL) was transferred to microcentrifuge tubes and lyophilized. A modification to an existing method for liquid-liquid extraction of BPA was developed (54) . Aliquots of 1000 mL of chloroform/ methanol (50:50) were added to each pellet, and the samples were mixed using an Eppendorf Thermomixer at 1400 rpm for 24 hours, followed by centrifugation at 10.2k rpm for 3 minutes. The supernatant was extracted and dried under vacuum, and 500 mL of acetonitrile was added to each tube. Each sample was filtered using a 0.2-mm Corning nylon syringe filter before high-performance liquid chromatography (HPLC) injections. Chromatography was performed using a Waters HPLC instrument (WAT 600E controller; 717 Plus Autosampler) with a fluorescence detector (WAT 2475) that has a linear A Waters Spherisorb ODS2 analytical column (4.6 3 250 mm; 5-mm particle size) with a Supelguard LC-18 guard column (2 cm 3 4 cm; 5-mm particle size). An acetonitrile/water mixture was used as the mobile phase, with a steep gradient beginning at 50% and ending at 100% of acetonitrile over a period of 6 minutes at a flow of 1 mL/min (55) . Each 10-mL HPLC injection was excited with 225 nm of light, and fluorescence was collected at 305 nm. Chromatograms showing the fluorescence emission as a function of time were collected for samples that originated from mouse amniotic fluid and for control samples consisting of BPA in acetonitrile (1 mM and 1 nM concentration, respectively), acetonitrile, and water. The retention times of BPA in the chromatograms from the control samples were compared with those from the mouse samples to verify the presence of (untransformed) BPA and to estimate the amount present in the amniotic fluid. The limit of detection of control solutions of BPA is subpicomolar in concentration; however, to estimate the amount of BPA present in the samples, we relied on the linearity of the BPA fluorescence intensity as a function of concentration. The calibration curves generated showed that BPA from control solutions showed a fluorescence intensity that was linear with the concentration to picomolar quantities. The average concentration of BPA in the amniotic fluid from pregnant mice on E16.5 at 1 hour after intraperitoneal injection was 0.13 nM (data not shown).
Mammary whole mount morphological and IHC analyses
For morphological analysis of early-life (4.5 weeks of age) carmine-aluminum stained mammary whole mounts, epithelial elongation was measured in millimeters plus or minus from a line on the leading edge of the lymph node to the most distal point of epithelial branching. The number of TDEs was counted as the most distal ends of the epithelial ducts and branches. The number of TEBs was counted on these same mammary whole mounts, with the qualifying TEBs meeting a threshold of 0.15 mm in width. The percentage of epithelial area was determined at this early-life point, again on these same carminealuminum stained mammary whole mounts using color thresholding and selection in ImageJ (56) . The percentage of epithelial area was used to normalize the number of TEBs determined for each treatment and represented as a ratio. All measurements were performed on digital images obtained using a dissection microscope (Zeiss Stemi SV11 Apt stereomicroscope) at 0.63 magnification, equipped with a camera (AxioCam 506 color) and Zeiss ZEN software and confirmed through blind analysis ( Fig. 2 ; n $ 7).
For morphological analysis of adult (14 and 20 weeks of age) carmine-aluminum stained mammary whole mounts, the percentage of epithelial area was also determined using color thresholding and selection in ImageJ (56) . Digital images were obtained similarly using a dissection microscope and with one field of view from each biological replicate uniformly selected within the leading edge of the mammary gland in front of the lymph node (age 14 weeks, n $ 9; age 20 weeks, n $ 3). To further examine epithelial branching density and complexity, Sholl analysis was performed on the entire epithelial tree, as previously described (57) (n $ 9). Images were obtained using a dissection microscope at 0.63 magnification. In brief, the entire epithelial tree of each biological replicate was processed in ImageJ to optimize the contrast of the tree from the surrounding mammary fat pad, the background was subtracted and the noise removed. The grayscale image was thresholded and skeletonized to discern the pixels of interest. Sholl analysis was performed using the plug-in for ImageJ. Because this analysis was performed on whole mounted glands from 14-week-old mice, instead of using the point of epithelial tree origin, a centralized point behind the lymph node was chosen for all glands analyzed. Choosing such a point was previously reported to not affect the For IHC analysis of both early-life and adult glands, all sections were stained using a Bond Rx autostainer (Leica Biosystems, Buffalo Grove, IL) and automated software (Bond Rx, version 4.0) to run optimized protocols. In brief, the slides were baked at 65°C for 15 minutes, and automated software performed dewaxing, rehydration, antigen retrieval, blocking, primary antibody incubation, postprimary antibody incubation, detection [3, 3 0 -diaminobenzidine (DAB) or Bond Polymer Red Detection], and counterstaining using Bond reagents (Leica). The samples were then removed from the machine, dehydrated through ethanol and xylene, mounted, and coverslipped. Antibodies for the following markers were diluted in antibody diluent (Leica): rabbit antibody a-smooth muscle actin (SMA; 1:5000; Abcam, Cambridge, UK), ERa (1:2000; E115; GeneTex, Irvine, CA), and Ki67 (1:200, Abcam); and rat antibody cytokeratin 8 (1:2000; TROMA-I-C; Developmental Studies Hybridoma Bank, University of Iowa).
IHC dual-stained for both early-life and adult glands was analyzed by first taking four field-of-view images, per biological replicate at 203 magnification using the Vectra Automated Multispectral imaging system. For 4.5-week-old mice, mammary tissue, TDEs, and ducts were imaged, and for 14-week-old mice, mammary tissue, alveolar buds, and ducts were imaged, resulting in four images per structure in each biological replicate. Tissue compartment segmentation and quantification of positivity was performed manually using InForm Advanced Image Analysis Software, version 2.0.2 (Perkin Elmer, Waltham, MA). Specifically, the InForm Tissue Finder software was used to determine tissue compartment positivity, which consisted of the following (1): performance of manual tissue compartment segmentation using SMA-positive staining as a designation of the epithelial compartment; (2) identification of positive cells using by the object-based segmentation functionality; and (3) scoring using 2-bin positivity to identify the component DAB signal as positive for the staining performed (ERa or Ki67) and a threshold to differentiate between DABpositive and DAB-negative (hematoxylin and eosin only) cell nuclei. Scoring was performed separately for each tissue compartment, the thresholds for positivity were determined for each compartment and applied across all images, and the results were presented as the percentage of positive values normalized to the area of the total tissue using the InForm software.
Statistical analysis
Data were analyzed using analysis of variance, followed by post hoc comparisons. The multiplicity was adjusted using the Holms-Bonferroni method to control the overall type I error rate at 0.05 (58) . Pearson correlation and linear regression methods were used to evaluate the association between the percentage of ERa-or Ki67-positive cells and epithelial elongation. SAS, version 9.4, software was used for data analysis (SAS Institute, Inc., Cary, NC).
Results
In utero ERa expression in developing mammary gland is strictly mesenchymal
Many of the defects associated with in utero BPA exposure were observed in the adult epithelium. The misappropriated activation of ERa has been postulated to be critical for the observed pathologies associated with increased cancer susceptibility. However, ERa has been reported to be expressed strictly in the mesenchymal cells surrounding the mammary epithelial bud in in utero mouse development (42, 59) . Thus, we first examined the expression of ERa in the developing perinatal mammary gland in the presence and absence of BPA (Fig. 1) . After in utero BPA treatment, ERa was examined by IHC in the developing mammary gland at E13.5, E15.5, E16.5, E17.5, E18.5, and E19.5. The expression observed at all in utero time points revealed that ERa was strictly expressed in the mammary mesenchyme surrounding the ERa-negative developing mammary epithelial bud ( Fig. 1; oil, magnification 320) . At the E13.5 and E16.5 time points, virtually all peripheral epithelial cells were in contact with ER-positive mesenchyme. Because the ERa-negative epithelial rudiments extended toward the mammary fat pad and past the primary ERa-positive mesenchyme (after approximately E15.5), more ERnegative stromal cells were in contact with the peripheral epithelial cells ( Fig. 1 ; oil E18.5, magnification 320; oil E18.5, magnification 310). In utero exposure to BPA showed expression of ERa similar to that of the oiltreated controls ( Fig. 1; BPA, Bottom) .
In utero windows of BPA treatment cause varying degrees of mammary gland phenotypes in the developing gland
To date, previous studies have focused on exposures spanning all of in utero mammary gland development. To assess whether the various stages of in utero mammary development have different susceptibilities to BPA exposure, we used four specific dosing schemes structured around the mammary gland in utero developmental milestones to assess whether a window of exposure would best account for the well-characterized later-life epithelial defects [ Fig. 2(a) ]. The windows of BPA exposure were designed to include the period during milk line formation but before bud invagination into the mesenchyme (BPA1, E8.5 to E12.5); the period from milk line formation through bud invagination (BPA2, E8.5 to E16.5); the period in which epithelial extension begins toward the fat pad until it has begun branching (BPA3, E15.5 to E18.5); and the duration of exposure that resulted in previously reported phenotypes (BPA4, E8.5 to E18.5). Pregnant mice were injected IP daily with oil or 25 mg/kg body weight BPA for the indicated periods between E8.5 and E18.5 [ Fig. 2(a) ]. Using carminestained mammary whole mounts of in utero-treated 4.5-week-old mice, we found that the previously reported delayed epithelial growth phenotype was dependent on the in utero window of BPA treatment received. Specifically, epithelial elongation from the leading end of the mammary gland lymph node [ Fig. 2(b) , dashed line] to the most distal epithelial branching [ Fig. 2(b) , solid line] demonstrated a clear defect in mice treated after E12.5. Mice treated before E12.5 (BPA1) had elongation similar to that of the control mice. However, epithelial elongation in the mice treated at other in utero windows, BPA2 (P , 0.001) and BPA3 (P , 0.05) was significantly less than that of the control mice and was similar to that of mice treated throughout all in utero mammary development [BPA4; P , 0.001; Fig. 2(b) ; n $ 7]. Early-life glands showed that only BPA4 treatments demonstrated a statistically significant reduction (P , 0.005) in the number of TDEs [ Fig. 2(c) and 2(d)] . Although showing the trend of a decreased number of TDEs, the differences in BPA2 and BPA3 did not reach statistical significance. Furthermore, recapitulation of the phenotypes observed in previous studies included an observed increase in the ratio of TEBs [ Fig. 2(c) and 2(e) ] to the total epithelial area in the treatment periods after E12.5 [ Fig. 2(d)] , with the differences at BPA4 statistically significant (P , 0.005). However, the differences at BPA2 and BPA3 demonstrated a phenotypic trend that did not reach statistical significance.
Using mammary gland tissue sections from the matched inguinal glands of the 4.5-week-old mice, we examined ERa expression and proliferation (Ki67) in both the epithelial tissue compartment and the stroma surrounding the TDEs (these included TEBs) after varied in utero BPA treatment. IHC staining of SMA was used as a marker to differentiate the epithelial tissue compartment from the surrounding stroma. Positivity for ERa and Ki67 was determined within the epithelium and stroma for each treatment [ Fig. 3 positivity in the stromal compartment surrounding the TDEs was significantly increased with BPA2 (P , 0.05), BPA3 (P , 0.05), and BPA4 (P , 0.001) treatment compared with the controls and BPA1 was not [ Fig. 3(a) ]. In contrast, Ki67 positivity in the stromal compartment surrounding the TDEs was significantly decreased in the BPA2 samples (P , 0.001), with a trend toward decreased Ki67 positivity with BPA3 and BPA4 treatment compared with the control without reaching statistical significance [ Fig. 3(b) ]. Ductal Ki67 positivity was also quantified in both tissue compartments, with no substantial changes observed across the treatment windows (data not shown). Molecular changes, both ERa and Ki67, in TDE epithelium were only substantial in BPA4 [ Fig. 3(a) and 3(b) ].
Early-life dysfunction of mammary gland epithelial elongation [ Fig. 2 Varied in utero windows of BPA treatment change later-life ERa expression in the tissue compartments of the mammary gland
To evaluate whether the early-life defects (Figs. 2 and 3) propagated to later-life mammary development, we considered the morphological and molecular changes in adult 14-week-old mice after our different windows of in utero exposure. Examining dual-stained tissue sections taken from in utero-treated 14-week-old mice, we found that each treatment window had different ERa-positivity profiles, especially for the epithelial-alveolar structures and surrounding stroma ( Fig. 4 ; n $ 4). Consistent with the pubescent developing mammary gland, BPA1 mice showed unchanged ERa positivity in both the stromal and the epithelial compartments of the adult mammary gland compared with that in the controls. Comparable to BPA1, BPA3 mice also showed no changes compared with the controls in either tissue compartment. However, ERa positivity was significantly decreased after BPA4 treatment compared with the controls in both tissue compartments (P , 0.05). Although the differences after BPA2 treatment did not reach statistical significance in stromal ERa positivity compared with the controls, the differences were significantly decreased in the epithelial compartment (Fig. 4) . Ki67 positivity was not significantly different from that of the controls in any treatment or tissue compartment in the adult mammary gland (data not shown).
In utero BPA exposure alters ductal morphology to varying degrees based on window of treatment
To evaluate the ability of our model to recapitulate previous reports that in utero BPA exposure increases the epithelial volume and alters ductal morphology (4, 18), carmine-stained mammary whole mounts of adult 14-week-old [ Fig. 5(a) ; n $ 9] and 20-week-old [ Fig. 5(b) ; n $ 3) mice were examined. Similar to the trends seen for ERa staining at 14 weeks of age (Fig. 4) , BPA2 and BPA4 exposure resulted in statistically significant increases in epithelial area [ Fig. 5(a) ; P , 0.05]. However, no change was observed in with BPA1 and BPA3. This phenotype was consistent through 20 weeks [ Fig. 5(b) ; P , 0.05]. BPA1 and BPA3 treatment did show a trend toward increased epithelial area at the later time point of 20 weeks; however, the difference did not reach statistical significance (P = 0.051 and P = 0.082, respectively). Further investigation of the alterations to the mammary Figure 4 . In utero BPA changes later-life ERa expression of mammary tissue compartments. Representative IHC of oil and varied with BPAtreated in utero mammary glands from adult 14-week-old mice, dual-stained (as in Fig. 3 ) with SMA and ERa focused on alveolar structures (magnification 320). epithelium was performed using Sholl analysis to measure the branching density and complexity in 14-week-old mice (57) . BPA2 (P , 0.05) and BPA4 (P , 0.0001) treatment demonstrated significantly more intersections compared with control mice (Table 1 ; sum N). The findings in the BPA1 group were indistinguishable from those of the control mice. BPA3 treatment showed a trend was comparable to that seen in the BPA2 and BPA4 mice, but the differences did not reach statistical significance compared with the controls (P = 0.13). Furthermore, the branching density (N/mm 2 ), which normalizes the number of intersections to the total area of the mammary gland epithelium revealed a statistically significant difference compared with the controls, again in both BPA2 (P , 0.005) and BPA4 (P , 0.001; Table 1 ). Branching complexity, or the calculated Sholl regression coefficient, is described by the degree that branching continues in distal regions of the epithelial tree (57). The calculated value for the coefficient was significantly lower in BPA2 (P , 0.05) and BPA4 (P , 0.0001) compared with the control, indicating that epithelial branching was more consistent or complex throughout the entire epithelium (57). BPA3 followed this trend without reaching statistical significance (Table 1 ; P = 0.053). Taken together, these data revealed that most in utero BPA phenotypes throughout development can be recapitulated and propagated to adult life, solely by exposure after E12.5.
Discussion
Susceptibility of mammary gland to BPA exposure is not uniform throughout gestation
In utero endocrine-disrupting chemical exposure initiates detrimental effects on hormone-dependent organogenesis that increase the risk of developing cancer. Studies of DES daughters demonstrated that exposure Figure 5 . In utero BPA significantly alters the density and complexity of the mammary epithelium. Epithelium quantitation shown by color thresholding in ImageJ as pixels in epithelium as a percentage of total pixels in field of view. Representative dissection light-microscope images of carmine-stained mammary gland whole mounts from adult mice at (a) 14 weeks old and (b) 20 weeks old treated with oil and varied in utero BPA windows (as described in Fig. 2 ). Graphs present percentage of area of epithelium as quantified by ImageJ. Each dot represents separate biological replicates: (a) n $ 9 and (b) n $ 3. Open circles indicate mammary gland representing that treatment, as shown. *P , 0.05. Data presented as mean 6 standard error of the mean.
Abbreviations: CV, coefficient of variation; log (N/mm 2 ), intersections per mammary epithelial area less area occupied by lymph node or branching density; Sum N, total intersections in mammary epithelial area. a Or branching complexity; slope of log (N/mm during the first trimester resulted in the greatest risk of developing vaginal cancer (2, 60, 61) . However, no similar analysis has been performed to identify a specific window of susceptibility for breast cancer. Although BPA has been shown increase TEBs and cancer risk in rodents, similar to the in utero effects of DES (25) (26) (27) , the developmental mechanism of this disruption and propagation to later-life endpoints remains unclear. We thus tested various windows of in utero exposure to BPA according to the stages of murine mammary gland development (42, 62, 63) . Using this model of four BPA dosing schemes, we found that developmental defects in the mammary gland were observed when the mice were treated after the epithelial bud had invaded the ERapositive mesenchyme (after E12.5). BPA1 (E8.5 to E12.5) elicited little to no evidence of any previously reported defects. Consistent with the previously reported phenotypes, BPA2 and BPA4 (after E12.5 through E18.5) were found to exhibit substantial defects. At our early-life time point of 4.5 weeks old, BPA exposure resulted in delayed epithelial elongation and a trend toward both a reduced number of TDEs and an increased ratios of TEBs normalized to the total epithelial area [ Fig. 2(b) and 2(c) ]. Although most BPA treatment windows (BPA1 to BPA3) recapitulated the previous finding that proliferation within the epithelial compartment of the TEBs, our BPA4 exposure, in contrast, resulted in a substantial decrease in proliferation (Ki67 positivity) compared with the controls. However, this discrepancy could have been because this measurement was performed in a mixture of TDEs and TEBs, because we did not qualify TEBs specifically using a size threshold. Overall, most of the substantial early-and later-life phenotypes were observed in windows of exposure that included E12.5 to E16.5 (BPA2 to BPA4).
The developmental window E12.5 to E16.5 correlated with a time when the potential for the most direct and complete influence of the ERa-positive mesenchyme on the ERa-epithelium was observed ( Fig. 1; E13 .5 and E16.5). BPA3 only exhibited a partial phenotype, not reaching statistical significance in any of the later-life molecular and morphological phenotypes observed. BPA3 treatment corresponds to an in utero time in mammary development when the elongating ERa-negative epithelial rudiments are no longer completely surrounded by the ERa-positive mesenchyme.
A potential caveat of our model was that the most influential treatments, BPA2 and BPA4, also spanned the longest period of in utero development (8 and 10 days vs 4 and 3 days for BPA1 and BPA3, respectively). However, it is important to recognize that BPA3, although only spanning 3 embryonic days of exposure, did result in a substantial but diminished phenotype. In contrast, the BPA1 window, spanning 4 days, resulted in no observable changes to the mammary gland. Thus, the duration of exposure was not the principle driver of the observed defects. Furthermore, owing to the rate of clearance of BPA from mice, exposure to BPA persisted after the treatment window. For example, although the BPA2 treatment group received a final BPA dose on E16.5, previously reported findings have demonstrated that BPA administered by 10-mg/kg intraperitoneal injections (40 times higher than the dosage used in the present study) only becomes undetectable 18 to 24 hours after injection (64) . Thus, the exact exposure period extends beyond the treatment windows and cannot be discretely demarcated. Nonetheless, the different windows in our model produced varying degrees of mammary gland phenotypes, and treatment before E12.5 produced defects that were not influential for most endpoint measures.
Role of ERa in mediating effects of in utero BPA exposure
The effects of BPA have long been suspected to elicit deregulated mammary development and later-life susceptibilities through its ability to bind and differentially activate the ERs (7, 8, (65) (66) (67) (68) . Evidence has suggested that ERa activation in the stroma might be the driver of BPA-induced defects (21, 22, 44) . More recently, BPAinduced defects in mice were shown to be blocked by treatment with the estrogen antagonist fulvestrant, suggesting that BPA might act through nuclear ERs in the stroma (69) . Together with the present work, these findings support classic findings that the stroma plays a pivotal role in later epithelial morphogenesis (63, (70) (71) (72) and extends the effect of the stroma to be involved in the mechanism of disruption by BPA to affect later-life susceptibilities. Thus, the BPA-induced mesenchyme might reprogram the epithelium through paracrine signaling after inappropriate ERa activation. Therefore, one would predict that paracrine signaling would have the most influence at the point in mammary development when the epithelial bud is completely surrounded by ERa-positive mesenchyme. Our BPA2 and BPA4 treatment windows displayed the most substantial phenotype from BPA exposure. This period represents the time beginning at E12.5, when the developing epithelial placode has extended into the underlying dermis and ERa-positive mesenchyme (42, 71) . At E16.5, the epithelial bud sprouts out of the mesenchyme and toward the fat pad [ Fig. 1 ; diagrammed in Fig. 2(a) ]. Although ERa-positive stromal cells are observed around the extending epithelial bud at this later time point, most expression remains near the nipple sheath ( Fig. 1; E18.5, magnification 310) . Thus, ERa-dependent paracrine signaling after bud extension might be affecting a smaller percentage of the developing epithelium. This possibility was highlighted by mice treated after the epithelial bud had begun to elongate toward the fat pad (BPA3), which demonstrated an important epithelial phenotype in early development [ Figs. 2(b) and 3(a) ] but failed to show substantial defects in the adult gland (Figs. 4 and 5 ; Table 1 ). This finding suggests that either the influence of BPA-mediated paracrine signaling during this time is weaker or some phenotypes are induced through ER-independent mechanisms.
Previously, it was shown in mice that only 4% of stromal cells are weakly ERa-positive immediately in postnatal development and that the expression continues to increase in intensity and number of positive cells through puberty and adulthood (59) . ERa positivity within the control-treated early-life mammary gland recapitulated this finding [ Fig. 3(a) ]. BPA causes an increase in ERa-expressing cells of the TDEs at 4.5 weeks (BPA4) compared with the significantly reduced epithelial expression at 14 weeks, such as was observed in BPA2 (P , 0.05) and BPA4 (P , 0.05). The importance of ERa signaling in the stroma of the developing mammary gland has until recently remained unclear. A recent study showed that BPA can directly alter mammary gland development in an ex vivo model system that eliminated the effects BPA might have on the hypothalamic-pituitarygonadal axis. These data support the hypothesis that BPA acts directly on the ERa-positive stroma to influence mammary gland development.
The demonstrated ability of BPA to interact with other hormone receptors, including ERb and a membranebound receptor (GPR30 or GPER), that act on mammary gland development cannot be dismissed. Consequently, both receptors, similar to ERa, initiate hormone-responsive activity and signaling effects (8, 65, 66, 73, 74) . However, it is clear from knockout models of these receptors that ERa predominantly facilitates later-life mammary gland development (35) (36) (37) (38) 73) . Furthermore, mice displaying the most mammary gland defects (BPA2) were exposed during a period in which ERb expression is not detected in the developing epithelial bud (E18) (22) . Taken together, our exposure model supports the idea that BPA specifically acts on in utero mesenchymal ER-positive cells to reprogram signaling and impart later-life defects observed. This emphasizes that ERa activation must be critical for BPA disruption of mammary gland development.
The effect of ERa signaling in our murine model, however, could have been convoluted by the potential differences in mammary gland in utero expression of the receptor in mice and humans tissue compartments. Although mice lack epithelial ERa expression until after birth, humans express the receptor beginning after week 30 of gestation. Furthermore, no human study has ever demonstrated in utero mesenchymal ERa expression. Few studies have considered ERa expression before week 18 of gestation in the human mammary gland (75) (76) (77) , and no study has done so before week 12. The period of mouse development most susceptible to in utero BPA exposure in our mouse model (E12.5 to E16.5) corresponds to weeks 7 to 14 of human gestation, well before any ERa epithelial expression in humans (59) . This period represents the end of the first trimester of human gestation and was also the window in which susceptibility to vaginal cancer and, in particular, in which vaginal misdifferentiation defects were found to be the highest (2, 78) . Although no study has correlated breast cancer susceptibility to the timing of exposure, one study did correlate these vaginal defects to breast cancer risk (2, 3) . These combined data suggest that human susceptibility to cancer in the mammary gland occurs before epithelial ERa expression in the third trimester.
Effect of stromal signaling on mammary defects
Our model of discrete in utero windows of BPA exposure further supports the long-established importance of stromal-epithelial interactions in mammary gland morphogenesis (63, 70, 71, 79) . Estrogenic compounds can act directly on mammary gland tissue to effect epithelial development despite the lack of ER expression in the epithelium (69) . Furthermore, the fetal transcriptomes of each tissue compartment were specifically and differentially altered by BPA exposure, highlighting the potential of BPA to disrupt the interactive partnership between the epithelium and stroma in the developing breast (22) . However, it is unclear whether these changes to the transcriptome are both necessary and sufficient to drive adult phenotypes and the susceptibility to cancer.
The interactions between the respective tissue compartments are vital in the development of the breast, and disruption can promote tumorigenesis (71, (79) (80) (81) (82) (83) (84) . Thus, determining the influence in utero BPA exposure has on these vital processes and receptor signaling is paramount in determining the mechanism by which BPA mediates later-life breast cancer susceptibility. In early development of the mammary gland after in utero exposure to BPA, we found a significantly increased number of ERapositive stromal cells surrounding the TDEs [ Fig. 3(a) ]. Because ERa-positive stromal cells are reported to increase during puberty (59, 85) , this observation might suggest that the mammary glands are undergoing precocious puberty. Furthermore, stromal ERa staining has been previously shown to be confined to undifferentiated mesenchymal cells rather than to adipocytes or fibroblasts (85), suggesting an increase in mesenchymal stem cells, which are known to promote tumor growth and metastasis. Thus, BPA might stimulate epithelial development indirectly through stromal ERa-positive progenitors (18, 19, 29, 81, 86) .
Conclusions
Our murine in utero model showed substantial defects in the developing mammary epithelium (Figs. 2-5 ) despite their lack of ERa expression at BPA exposure (Fig. 1) . These important developmental defects were associated with in utero treatment that occurred when the mammary epithelial bud was completely surrounded by the ERaexpressing mesenchyme [E12.5 to E16.5 (BPA2 to BPA4); Figs. 1 and 2(a)]. Our findings reinforce the idea that the timing of exposure, even within the perinatal period, can have important influences on later-life cancer susceptibility. This idea tragically proceeds from the treatment of pregnant women with both DES in the 1940s and thalidomide in the 1950s. Both drugs elicited developmental defects in offspring specific to the in utero exposure received (2, 87) . In the case of DES, the comprehensive follow-up report emphasized that women exposed in utero who were $40 years old had a twofold increased incidence of breast cancer (1-3). The risk was more pronounced for women with vaginal epithelial changes previously shown to be associated with first trimester exposures. In humans, the initial mammary bud invades the parenchyma during the eighth week of gestation, correlating to E12.5 of murine development (59) . It was evident from our investigation that this period elicited the most detrimental epithelial defects in both early and adult mammary development. Thus, these data implicate reprogrammed ERa activation in the fetal stroma as a mediator of later-life mammary gland defects after exposure to estrogenic compounds in the environment. Our work clarifies the need to demonstrate the requirement of ERa expression in the stroma during in utero exposure to BPA. 
